BostonBioForum 2013

二〇一三美中生物医药协会年会

Chinese American BioMedical Association (CABA)
2013 Annual Conference

Accelerating Drug Development - from Bench to Bedside

从实验室到临床 - 加速药物开发

Time: Saturday April 27 (8:00am—9:00pm)
Venue: MIT Faculty Club, 50 Memorial Drive. Bldg E52, 6th floor, Cambridge, MA 02139

Themes/Topics

- Industry Trends & Key Technology Innovations
- Globalized R&D: Resourcing & Collaborations
- Career Development & Entrepreneurship
- Networking Receptions & Vendor Exhibitions

CABA Chinese-American BioMedical Association 美中生物医药协会

Chinese-American BioMedical Association (CABA)
Organizing Committee of Boston BioForum 2013 – CABA Annual Conference

Excellence in Innovation

Ariad Pharmaceuticals

In recognition of its outstanding contributions and achievements in the development of Iclusig™ (ponatinib), a treatment for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to existing therapies.

April 27, 2013
Cambridge, Massachusetts, USA

Chinese-American BioMedical Association (CABA)
Organizing Committee of Boston BioForum 2013 – CABA Annual Conference

Excellence in Innovation

Ironwood Pharmaceuticals

In recognition of its outstanding contributions and achievements in the development of Linzess™ (linaclotide), a treatment for adult patients with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

April 27, 2013
Cambridge, Massachusetts, USA

BostonBioForum 2013

二〇一三美中生物医药协会年会

Chinese American BioMedical Association (CABA)

2013 Annual Conference

"Accelerating Drug Development - from Bench to Bedside"

加速药物开发：从实验室到临床

Admission

CABA members: FREE; Non-members: $30; Students: $15

On-site membership registration to CABA is available. ($30 annual membership fee due), you can also register online at www.cabaweb.org.

Reception Dinner

You are also welcome to stay for dinner (starting at 6:00pm). Tickets ($40) are available on-site at registration table.

Driving Direction & Parking

Faculty Club: http://web.mit.edu/facultyclub/about/directions.html

Please use MIT E51 lot and Hayward lot for parking. Parking at MIT on Saturday is **free**.

For information about CABA and upcoming events, please check CABA Web site: www.cabaweb.org.

Conference Organizing Committee

Chair

XIANG YANG YU

Co-Chairs

ZHIHONG CHEN SHIWEN LIN ZHAO-KUI (ZK) WAN

YIHAN WANG PHILIP ZHANG

Committee

QINGQING CAO, QINGLIN CHE, CHAOYANG DAI, ELLEN FAN, KEVIN FANG, SHENGFANG JIN, JO LEE, HAO LI, CARRIE LIU, FANG LIU, SUSAN QU, LIXIN SHEN, JI SHI, ZE TIAN, YIKAI WANG, ZHIGANG WANG, LI XING, ZHIYONG YANG, YOUXIN ZHANG, ZHENDONG ZHU

Conference Agenda

8:00-9:00 *Registration*

9:00-9:05 *Opening Remarks*
Conference Chair: **Xiang Yang Yu, PhD**

MORNING SESSION I
SESSION CHAIRS: XIANG YANG YU, SHENGFANG JIN, JI SHI

9:05-9:30 *Development of Linaclotide for the Treatment of Chronic Functional Gastrointestinal Disorders*
Angelika Fretzen, PhD
VP Pharm. Chem. & Dev., Ironwood Pharmaceuticals

9:30-9:55 *Science and Strategy at Agios*
Scott Biller, PhD
Chief Scientific Officer, Agios Pharmaceuticals

9:55-10:20 *Sooner Rather Than Later: Pricing and Market Access in New Product Planning*
Juan F. Rivera, MBA
Simon-Kucher and Partners LLC

10:20-10:50 **Coffee Break and Vendor Show (Sponsored by *Sundia*)**
Hosts: Fang Liu, Carrie Liu

MORNING SESSION II
SESSION CHAIRS: LI XING, ZHIHONG CHEN, QINGQING CAO

10:50-11:15 *a Virtual Biotech Success Story - from Deuteria Pharmaceuticals to DeuteRx*
Sheila Dewitt, PhD
President and CEO, DeuteRx

11:15-11:40 *from Patient to Patient for Cancer Therapeutics, the H3 Approach*
Yuan (John) Wang, PhD
VP Medicinal Chemistry, H3 Biomedicine Inc

11:40-12:05 *Humanized Mice for Preclinical Drug Development*
Jianzhu Chen, PhD
Ivan R. Cottrell Professor of Immunology, MIT

12:05-1:00 **Lunch Break, Vendor Show and Career Fair (Sponsored by *Wuxi AppTec*)**
Hosts: Fang Liu, Carrie Liu

AFTERNOON SESSION I
SESSION CHAIRS: YIHAN WANG, HAO LI, CHAOYANG DAI, SHIWEN LIN

1:00-1:25 *Design and Development of Ponatinib, a Pan-BCR-ABL Inhibitor for CML*
Timothy P. Clackson, PhD
President of Research and Development and CSO, ARIAD Pharmaceuticals

1:25-1:50 *Janssen Innovation Centers: Integrating a Global Science Village to Improve Patient's Lives*
Pamela Carroll, PhD
VP Oncology Scientific Innovation at Janssen, Companies of Johnson and Johnson

1:50-2:15 *Bedside to Bench [to Bedside] - A Tumor's Tale*
Michael Briggs, PhD
President and CSO, Woodland Pharmaceuticals

2:15-2:40 *40 Years in the Industry: from Basic Research to Repositioning*
Elkan Gamzu, PhD
Chairman, Hygeia Therapeutics & NeuroHealing Pharma., Inc

2:40-3:15 **Coffee Break and Vendor Show (sponsored by Anichem)**
Hosts: Fang Liu, Carrie Liu

AFTERNOON SESSION II
SESSION CHAIRS: PHILIP ZHANG

3:15-4:00 **Panel Discussion:** *Alternative Careers for Biomedical Scientists: Legal, Investment, Business*
Moderator: **Philip Zhang, PhD, JD**

Hui Cai, PhD, MBA, VP	Wuxi AppTec
George Dai, PhD,	Weatherbie & Co., Inc.
Areta Kupchyk, JD, Partner	NixonPeabody
Jason Wen, PhD, MBA, CLP, RTTPUSPTO	Boston College
Philip Zhang, PhD, JD	Milstern Zhang & Wu LLC

4:00-5:15 **Round Table Panel Discussion***: Global Integrated R&D Collaboration*
Moderator: **Shengfang Jin, PhD**

Alex Burgin, PhD, CSO	Emerald Bio
Chen Chen, PhD, CEO	Sundia
Shengfang Jin, PhD	Agios Pharmaceuticals
Fu-An Kang, PhD, VP	Wilmington PharmaTech
Donghui Qin, PhD, Manager	GlaxoSmithKline,
Jeff Saunder, PhD, VP	Ember Therapeutics
George Shi, PhD,CSO,	Anichem, Inc.
Frederic Somny, PhD, Head	Business Development, Piramal Discovery Solutions
Max Wang, PhD, CBO	Akeso Biopharma, Inc.
Zengquan Wang, PhD, CBO	Viva
Chengbin Wu, PhD, VP	Biologics, Shanghai ChemPartner
Charles (Yuanzan) Ye, CEO	Acesys Pharmatech
Libing Yu, PhD, founder, CEO	Alputon
Xiang Yang Yu, PhD	Ironwood Pharmaceuticals
Jason Zhang, PhD, President	Acme Bioscience, Inc.

5:15-6:00 **Cocktail Social Hours: Networking and Vendor Show (Sponsored by *Wuxi Apptec*)**
Hosts: Fang Liu, Carrie Liu

EVENING SESSION
SESSION CHAIRS: PHILIP ZHANG, ZHAO-KUI (ZK) WAN

6:00-7:00 **Dinner**

7:00-7:10 *CABA 2012-13 and New CABA Leadership Team*
Philip Zhang, PhD, JD
President, CABA

7:10-7:40 *Designing Oral & Inhaled p38a MAP Kinase Inhibitors to Treat Asthma & COPD*
John Mathias, PhD
Head of Medicinal Chemistry for the Inflammation & Remodeling Group, Pfizer

7:40-8:10 *Building a Biotech Company from the Ground Up*
Roger Tung, PhD
President and CEO, Concert Pharmaceuticals

8:10-9:00 **Social Networking**

BIOSKETCHES AND PROGRAM SUMMARY

Angelika Fretzen, PhD, VP, Ironwood Pharmaceuticals

Presentation Title: *Development of Linaclotide for the Treatment of Chronic Functional Gastrointestinal Disorders*

Angelika is the Vice President of Pharmaceutical Chemistry & Development at Ironwood Pharmaceuticals. She joined Ironwood (formerly Microbia) in January 2001, and has played an integral role in both building the medicinal chemistry department and establishing state-of-the-art processes for creating and selecting drug candidates. Since 2004 she has added Pharmaceutical Development to her responsibilities and has led efforts pertaining to the chemical, analytical and formulation development of Ironwood's clinical candidates. Angelika joined the linaclotide team to lead CMC related aspects of the program all the way to approval in the US and in Europe. Prior to joining Ironwood, Angelika Fretzen was an Alexander von Humboldt Fellow in the Department of Chemistry and Chemical Biology at Harvard University. Angelika received her MS in organic chemistry from the University of Würzburg in Germany and completed her Ph.D. at the Université de Genève in Switzerland. She obtained an MBA from Suffolk University in Boston.

Scott A. Biller, PhD, Chief Scientific Officer, Agios Pharmaceuticals

Presentation Title: *Science and Strategy at Agios*

Scott joined Agios Pharmaceuticals as Chief Scientific Officer in September of 2010. Previous to Agios, he was Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research, responsible for the world-wide chemistry functions. Prior to Novartis, Scott was Vice President, Pharmaceutical Candidate Optimization and Executive Director of Metabolic Diseases Chemistry at the Bristol Myers Squibb Pharmaceutical Research Institute. Under his leadership, the Metabolic Diseases Area discovered multiple clinical candidates, including three marketed drugs. Scott gained his SB degree at the Massachusetts Institute of Technology in 1976 and his PhD in Organic Chemistry in 1982 at the California Institute of Technology. He held an NIH Postdoctoral Fellowship in natural product synthesis at Columbia University (1982-1983). He has nearly100 patents and publications.

Juan F. Rivera, MBA, Managing Partner, Simon-Kucher and Partners US Division

Presentation Title: *Sooner Rather Than Later: Pricing and Market Access in New Product Planning*

Juan is Simon-Kucher's US Managing Partner and joined Simon-Kucher and Partners LLC, the US arm of Simon-Kucher, in its start-up phase and has led many efforts to scale up the Company. He is an expert in pricing, reimbursement and commercial strategy in the life sciences. He has advised more than 20 global pharmaceutical, biotechnology, medical device and diagnostic companies in more than 15 countries. He has crafted strategies for 2 of the world's 10 best-selling drugs and has advised on the launch of over 25 products including many specialty therapies. Prior to joining Simon-Kucher and Partners, Juan worked for Cooper Industries, where he completed the corporate management training program and held various domestic and international assignments. Juan received an MBA with High Honors from Boston University and a BS in Industrial Engineering from Texas A&M University.



Sheila DeWitt, PhD, President & CEO, DeuteRx

Presentation Title: *a Virtual Biotech Success Story - from Deuteria Pharmaceuticals to DeuteRx*

Sheila is a Senior Life Sciences Executive & Entrepreneur with 25 years of experience in pharmaceutical and biotechnology companies. She is currently the President & CEO of DeuteRx, a virtual biotech company pioneering "Deuterium-Enabled Chiral Switching." DeuteRx is a spin-out company from Deuteria Pharmaceuticals, where Sheila was also President & CEO. As VP of Business Development, Discovery and Manufacturing at EPIX, she led the $125M merger to transition EPIX from imaging to therapeutics (EPIX-Predix), led the $28M sale of the 1st FDA approved MRA imaging drug (EPIX-Lantheus), and managed global R&D functions through Phase 2 trials. Sheila has founded/co-founded five companies (Diversomer, Orchid, Deuteria Pharmaceuticals, JSD Partners, DeuteRx) and led the turnaround of several Business Units (Orchid, ArQule). In addition to numerous publications, patents, and presentations, Sheila is internationally recognized as a scientific pioneer in combinatorial chemistry (Parke-Davis, Diversomer). She earned her B.A. in Chemistry from Cornell University and Ph.D. in Synthetic Organic Chemistry from Duke University.

John (Yuan) Wang, PhD, VP, H3 Biomedicine

Presentation Title: *from Patient to Patient for Cancer Therapeutics, the H3 Approach*

In April 2011, Dr. John Wang joined H3 Biomedicine from Eisai Inc. in Andover, where he was Discovery Chemistry Director in the Oncology Product Creation Unit. Previously, John held various scientific leadership positions. He made key contributions to the early discovery effort of Halaven™ (eribulin mesylate),* a recently FDA-approved cancer drug based on a complex natural product, Halichondrin B. He has led a global discovery team effort that resulted in the discovery of E6201, a naturally inspired drug candidate that is now in clinical trials in both psoriasis and cancer patients. In the past 10 years, his research effort has been focused on oncology drug discovery. Before joining Eisai, John completed his Ph.D. in organic synthesis under Professor Yoshito Kishi. He entered Harvard University for graduate study as a fellow from the Chemistry Graduate Program (CGP) between U.S. and China. He earned his B.S. in Chemistry from Fudan University in Shanghai, China.

Jianzhu Chen, PhD, Professor, MIT

Presentation Title: *Humanized Mice for Preclinical Drug Development*

Jianzhu is the Ivan R. Cottrell Professor of Immunology and Professor of Biology at Koch Institute for Integrative Cancer Research and Department of Biology at MIT. He is also the lead Principle Investigator of the Infectious Disease Interdisciplinary Research Group of Singapore-MIT Alliance for Research and Technology (SMART). Dr. Chen's research seeks fundamental understanding of the immune system as well as its application in disease intervention. Dr. Chen received a B.S. degree from Wuhan University in China and a Ph.D. degree from Stanford University. He was a postdoctoral fellow and then an instructor at Harvard Medical School before he joined the faculty in the Department of Biology at MIT. Dr. Chen is also a visiting professor at Institute for Molecular and Cell Biology in Singapore, Institute of Biophysics, Chinese Academy of Sciences in Beijing, and the First Affiliate Hospital of Jilin University in Changchun, China.

Timothy P. Clackson, PhD, **President of R&D & CSO, ARIAD Pharmaceuticals**

Presentation Title: *Design and Development of Ponatinib, a Pan-BCR-ABL Inhibitor for CML*

Tim Clackson is President of Research and Development and Chief Scientific Officer at ARIAD Pharmaceuticals Inc., an integrated global oncology company headquartered in Cambridge, Massachusetts and Lausanne, Switzerland. During his 18 year career at ARIAD, Dr. Clackson has held a series of increasingly senior positions, including CSO since 2003 and President of R&D since 2010. Dr. Clackson has overall operational and strategic responsibility for R&D at ARIAD, including drug discovery, preclinical and translational research, clinical development, and manufacturing and technical operations. From 1991 to 1994, Dr. Clackson was a postdoctoral fellow at Genentech Inc., where his research with Dr. James A. Wells on hormone receptors defined the now-established "hot spot" paradigm for protein binding interfaces. Dr. Clackson received his Ph.D. in Biology from Cambridge University in 1991. Dr. Clackson has published approximately 85 scientific papers and is a co-inventor on 15 issued US patents. He received his B.A. degree in Biochemistry from Oxford University in 1987.

Pamela Carroll, PhD, VP, Janssen

Presentation Title: *Janssen Innovation Centers: Integrating a Global Science Village to Improve Patient's Lives*

Pamela recently joined Janssen as Vice President of Oncology based at the new Innovation Center in Cambridge, MA. Dr. Carroll is a biologist with an extensive background in oncology drug discovery and genomics/genetics, and a passionate proponent of novel models to better align science across academics and industry. Formerly, Dr. Carroll was Vice President at Roche in Nutley, NJ as Oncology Discovery Site Head and Global Head of Pathway Biology. Prior to Roche, she was head of research at the Belfer Institute at Dana Farber Cancer Institute. Earlier in her career, Pam was Director of the Cancer Pathways Department at Merck. Her initial industry experience was in Applied Genomics at Bristol-Myers Squibb validating new targets for oncology and immunology. Dr. Carroll earned her B.A. in biology at St. Michael's College in Vermont, and a Ph.D. in Cellular and Developmental Biology at Stony Brook University. She was a postdoctoral scholar at Stanford University.

Michael Briggs, PhD, President, Woodland Pharmaceuticals

Presentation Title: *Bedside to Bench [to Bedside] - A Tumor's Tale*

Michael is the President and Founder of Woodland Pharmaceuticals and has over 19 years of experience in the pharmaceutical industry. He has led teams of scientists at large and small pharmaceutical companies ranging from Pfizer to Ligand and most recently at Vertex Pharmaceuticals where he was a Sr. Director of Biology. His primary focus has been in discovery research with a strong emphasis on relevance to human biology and translation to clinical success. Teams he has led or managed have advanced seven compounds into, or ready for, clinical development. Therapeutic areas included most recently oncology, antivirals, cardiovascular and lipid metabolism, metabolic disease and arthritis and inflammation. He brings his recent focus on improved oncology modeling, including in depth modeling of drug-resistant tumors and primary patient tumors to Woodland Pharmaceuticals, a company that is participating in advancing oncology translational research through the astute use of cancer cell lines and primary patient tumor samples.

Elkan Gamzu, PhD, Chairman, NeuroHealing Pharmaceuticals

Presentation Title: *40 Years in the Industry: from Basic Research to Repositioning*

Elkan has worked in the biopharmaceutical industry since 1971 when he joined Hoffmann-La Roche in CNS pharmacology. In 1985, he joined Warner-Lambert as Therapeutic Head, clinical research in cognition and psychiatry. In 1989, he joined Cambridge NeuroScience, as VP, Development, eventually becoming CEO. In 1998, he formed the consulting company, enERGetics and was a founder of BioPharmAnalysis, a due diligence company. In 2001-2, he served as Interim VP, Project Management Leadership for Millennium Pharmaceuticals Inc. Since 2004 he served as interim CMO of Hypnion and interim CEO of 3 publicly traded biotech companies. Currently, he is Chairman of NeuroHealing Pharmaceuticals, Hygeia Therapeutics, and Canterbury Laboratories, and is on the Board of Neurotech Pharmaceuticals, and Product Manager for RedHill Biopharma, a publicly-traded company. Elkan has published extensively on psychopharmacology, neurology and drug development. He is a former member of the Board of Governors of the New York Academy of Sciences.

Hui Cai, PhD, MBA, VP, WuXi AppTec

Hui is Vice President of Corporate Alliances at WuXi AppTec, a NYSE listed premier provider of comprehensive and integrated services across the whole spectrum of pharmaceutical R&D value chain with over 6,000 employees and FDA/EMA/OECD/SFDA inspected facilities in US and China. She brought to WuXi with expertise in strategic planning, business development, along with ten years of drug discovery experience at Johnson & Johnson Pharmaceutical Research and Development. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Hui received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper - Athena FlexMBA Scholar.

H. George Dai, PhD, Deputy Chief Investment Officer, M.A. Weatherbie & Co

George is Deputy Chief Investment Officer at M.A. Weatherbie & Co, an institutional asset management firm with $1 B under management. George co-founded the long-short hedge fund and serves as the Head of Alternative Investment. He is also a co-manager of the small and midcap growth funds. George joined M.A. Weatherbie & Co., Inc. in March 2001. From August 1999 through December 2000, he was an equity analyst with 1838 Investment Advisors, a money management firm in Philadelphia. George received his MBA from the Wharton School, University of Pennsylvania, (Director's List), and his Ph.D. in chemistry from Johns Hopkins University. Previously, he earned a B.S. from the University of Science and Technology of China (Hefei, China) and then was a pharmaceutical research scientist at Proctor & Gamble. A prized Bridge player, he holds four US patents.

Areta L. Kupchyk JD, Partner, Nixon Peabody's Health Services and Life Sciences

Areta is a partner in Nixon Peabody's Health Services and Life Sciences practices, providing counsel to clients on the U.S. Food and Drug Administration (FDA) regulation of drug, medical device, biotechnology, and biologic products. Formerly an Associate Chief Counsel for Drugs and Biologics and Assistant General Counsel for Litigation at the FDA, Ms. Kupchyk possesses a nuanced understanding of FDA regulatory procedure that allows her to insightfully navigate clients through all phases of product development, review, and approval, including approvals with market exclusivity.. Ms. Kupchyk also specializes in the FDA regulation of advertising and promotional activities, including the FDA's restrictions on off-label use.

Jason Wen, PhD, MBA, Director of TT&L, Boston College

Jason is Director of Technology Transfer & Licensing at Boston College, has a strong background in Life Science, Business and Patent Law, and ten years' experience in the field of technology transfer/licensing with academic institutions and biopharmaceutical companies. He has worked in the Office of Technology Transfer at Cold Spring Harbor Laboratory as an Assistant Director for more than eight years. As a former Assistant Professor in Virginia Commonwealth University, Dr. Wen has more than ten years scientific research experience with high level of knowledge in biomedical science. He graduated from Nankai University in China and holds a Ph.D. degree in Molecular Biology, MBA degree from University of Richmond, and finished one year law school studies in a J.D. program. Recently, Dr. Wen has been invited as a Venture Forum Business Plan judge and a speaker in 2013 Association of University Technology Manager (AUTM) Annual meeting.

Philip Zhang, PhD, JD, Co-Managing Principal, Milstein Zhang & Wu LLC

Dr. Zhang is a co-founder and co-Managing Principal of Milstein Zhang & Wu LLC, an intellectual property law firm based in the Boston area. His clients include Fortune 500 companies, universities, technology start-ups, and entrepreneurs. Dr. Zhang has extensive experience in a variety of technologies and industries such as life sciences, clean technologies, advanced materials, and medical devices and advises clients on IP strategies, product patent clearance, licensing, patent preparation and prosecution, R&D collaborations, venture funding, M&A and other transactions. Prior to starting his current firm, he was Special Counsel at Cooley LLP. He was also Chief IP Counsel of Ensemble Therapeutics Corp. and Patent Counsel at Genzyme. Dr. Zhang obtained his J.D. from Vanderbilt University Law School and his Ph.D. in organic chemistry from Dartmouth College. Dr. Zhang publishes and speaks frequently on various legal, technology and business topics, including two publications in the journal Nature Biotechnology. He is the current President of Chinese American BioMedical Association (CABA). He was also the founding President of Chinese American Intellectual Property Law Association (CAIPLA).

Alex Burgin PhD, CSO, Emerald Bio

Discussion Title: *Structure-Based Drug Design Gains Momentum with Affordable Workflows and Scale*

Alex Burgin received his Ph.D. from Indiana University in genetics, and completed a Damon Runyon postdoctoral fellowship at the National Institutes of Health. Alex was a group leader at Ribozyme Pharmaceuticals from 1994-1998 and an Assistant Professor of Biology at San Diego State University from 1998-2001. In 2001 Alex joined Emerald Bio as Director of Molecular Biology, became COO in 2005, and CSO in 2012. Alex has seen the growth of Emerald Bio from a specialized structural biology company to a protein resource company providing instrumentation, software and a diverse set of protein services.

Chen Chen. PhD, CEO, Sundia

Discussion Title: *Advantage and Challenge of Chinese CROs*

Dr. Chen has a Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry, China. He did a post-doc at Texas A&M University with Nobel Laureate, Professor Sir Derek H. R. Barton, and a post-doc at the University of Illinois, Chicago. Dr. Chen spent 15 years at Neurocrine as Scientist to Senior Director of Medicinal Chemistry. In his research and management positions at Neurocrine, Dr. Chen achieved many outstanding scientific and industrial accomplishments. Dr. Chen Chen has served as Sundia's Senior Vice President since 2009. And he has been appointed as CEO of Sundia in 2012. Dr. Chen has extensive experience in CNS drug research and GPCRs as drug targets. His research interests extend to clinic and preclinical pharmacokinetics of small molecules and the relationship with their chemical properties. Dr. Chen has so far published near 130 scientific papers in peer-reviewed journals. He is the co-inventor of over 25 US patents.

Shengfang Jin, PhD, Sr Dir. of Biology & Head of Strategic Outsourcing, Agios Pharmaceuticals

Discussion Title: *Building Innovative CRO Alliances to Enable Agios R&D*

Shengfang is Senior Director of Biology & Head of Strategic Outsourcing at Agios Pharmaceuticals Inc. She leads a discovery research team in the pioneering therapeutic areas of cancer metabolism and rare metabolic genetic diseases and oversees strategic CRO partnerships and operations in Asia across the entire preclinical R&D continuum. She brings 16 years of R&D experience in science and management across several Biotech/Pharma companies. Shengfang was Director of Molecular and Cellular Pharmacology at Gene Logic Inc, where her team launched new therapeutic utilities by repurposing drug candidates and Senior Scientist, Oncology Project Team Leader at Millennium Pharmaceuticals (now Takeda). She was Staff Scientist,

Gene Therapy and Biotherapeutics at TKT Inc (now Shire Pharmaceuticals). Shengfang earned a B.S. degree from Wuhan Univ, China, a Ph.D from Tufts Med School, and was an NIH Postdoctoral Fellow at Harvard Med School & Dana Farber Cancer Institute in Tumor Immunology and Molecular Genetics.

Fu-An Kang, PhD, VP, Wilmington PharmaTech

Discussion Title: *Wilmington PharmaTech - 10 Years of Pharma R&D Services*

Dr. Fu-An Kang is the Vice President at Wilmington PharmaTech in Newark, Delaware. He received his PhD degree in organic chemistry at Beijing Normal University, and conducted his postdoctoral research at Harvard University. He has fifteen years of academic and industrial experiences as an associate professor at BNU, a medicinal scientist at JNJ, and a research manager at STL and WPT. He has over fifty scientific publications, patents, chapters and abstracts. He is an invited speaker at the Johnson & Johnson PRD Science Day, the Gordon Research Conference, the American Chemical Society National Meetings, and the Chemistry Seminars at Universities and Institutions. He is an invited reviewer for many chemistry journals. He contributed to the chemical development of the anticancer drug Eribulin in the Eisai-Harvard collaboration, and received a Johnson & Johnson PRD Platinum Encore Award for the chemical development of the SGLT2 inhibitor Canagliflozin.

Donghui Qin, PhD, Manager, GSK

Discussion Title: *Virtual Drug Discovery in Big Pharma: a VPoC Experience in GSK*

Dr. Qin graduated with a B.Sc from University of Science and Technology of China, and a Ph.D. in Organic Chemistry from the graduate school of CUNY under the direction of Prof. Robert Bittman. After finishing the total synthesis of natural product – heliquinomycinone in Columbia University under the direction of Prof. Samuel J. Danishefsky, he joined Sunesis Pharmaceuticals in S. San Francisco. In 2002, he joined GlaxoSmithKline, and has been there since. He has many years of experience in novel antibiotics discovery. In 2008, he joined the newly formed Virtual Proof of Concept (VPoC) DPU in GSK to setup the virtual discovery unit. Later, he was embedded in a major CRO in Shanghai, China to lead the outsourcing effort in multiple fully integrated programs. This effort has lead to multiple clinical candidates for GSK. After returning to GSK research center in PA in 2011, he has assumed the role of the program (co)leader(s) of multiple discovery programs.

Jeff Saunder, PhD, VP, Ember

Discussion Title: *Collegiality in Outsourcing*

Jeff is Vice President, Small Molecule Drug Discovery of Ember. Prior to joining Ember in 2012, Dr. Saunders was the vice president, chemistry at Agios. Dr. Saunders also worked as a consultant at Elixir Pharmaceuticals, where he managed all chemistry and related intellectual property for five years. Prior to this, he held the position of principal investigator at Vertex Pharmaceuticals, where he worked for 14 years as chemistry head and project head for multiple programs. Previously, he was a research scientist at the Squibb Institute for Medical Research. Dr. Saunders received his B.A. in chemistry from Hope College in Michigan, earned his Ph.D. in synthetic organic chemistry at the University of South Carolina and held an NIH postdoctoral fellowship at the University of Pennsylvania.

Guo-qiang (George) Shi, PhD, CSO, Anichem

Discussion Title: *Anichem - A Niche CRO on Your Doorstep*

Guo-qiang (George) Shi is co-founder and chief scientific officer of Anichem, a pharmaceutical R&D company specialized in developing new technologies and products for drug discovery. Prior to that, George was a senior research fellow at Merck Research Laboratories, where he conducted research in the department of medicinal chemistry for ten years. Before coming to the US, he was a professor at Shanghai Institute of Organic Chemistry (SIOC) and served as associate director for the State Key Laboratory of Organometallic Chemistry of Chinese Academy of Sciences for four years. George obtained his B.Sc. degree from East China Normal University and a M. Sc. degree from Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences. He received his PhD with honors from the University of Lausanne in Switzerland and conducted his post-doctoral research in natural product synthesis with Prof. K.C. Nicolaou at the Scripps Research Institute. He authored and co-authored over 40 peerreviewed publications and was the inventor of more than 10 patents in drug discovery.

Frederic Somny, PhD, Head of BD, Piramal Discovery Solutions

Discussion Title: *Perspectives from an Indian Drug Discovery CRO*

Frédéric Somny obtained a Ph.D. in Organic Chemistry in 1998, from Professor Guy Solladié's stereochemistry laboratory at Louis Pasteur University in Strasbourg. From 1998 to 2000, he then worked as a Senior Scientist at Oxford Diversity (now Evotec). In 2000, he joined Cerep as a Project

Leader for Drug Discovery projects involving synthetic chemistry and CADD. In 2007, he joined Unipex Solutions where he was offered the position of Head of Development and Applications, promoting Chemistry Manufacturing and Controls services in the EU. In 2008 he then joined Albany Molecular Research Inc. (AMRI) as a Business Development Manager and his role notably included promoting the whole range of AMRI services in various European countries. In 2012, he finally joined Piramal Discovery Solutions as Head of Business development. In his new position, Dr. Somny is involved in all business activities and strategic development of Piramal Discovery Solutions.

Max Wang, PhD, CBO, Akeso Biopharma

Dr. Max Wang is the co-founder and chief business officer of Akeso Biopharma, Inc., a CRO company in Guangdong, China committed to establishing a powerful and efficient integrated research platform for biologics (especially antibodies) from lab to clinical trials. Max graduated from University of Science and Technology of China with a physics major, obtained his Ph. D. in computational & structural biology from Baylor College of Medicine in 1998, and worked in structure based drug discovery as senior scientist, division leader or executive consultant at New Century Pharmaceuticals, Inc., Trimeris Inc. (now part of Synegeva) and Ardea Biosciences, Inc. (now part of AstraZeneca) for more than 10 years. Max went back to China in the beginning of 2009 and joined Crown Bioscience, Inc. as executive director in Protein Engineering and Structure Based Technologies. Max was also Vice President of Taicang-Crown Biopharmaceutical Analysis, Inc. for two years.

Zengquan Wang, PhD, CBO, Viva Biotech

Discussion Title: *Advancing Novel Drug Targets with Scientific Breakthroughs at Viva Biotech*

Dr. Zengquan Wang graduated with a Ph.D. degree from Washington State University in 1991. After a successive five-year postdoctoral training, he assumed a faculty position in the Dermatology Department of the University of Michigan. In 1999, Dr. Wang joined OSI pharmaceuticals in Long Island, NY, where he started his small molecule drug discovery career. Since then, he had worked as drug discovery scientist for Pfizer and AstraZeneca in therapeutic areas of dermatology, inflammatory diseases and oncology, respectively. Over the years, he has led multiple projects from ideas to finding novel drug candidates, a few of which were advanced to FIH. Dr. Wang also published over 20 articles in highly cited journals, such as the New England Journal of Medicine, Nature, Nature Medicine, and JCI either as the first author or co-author. Dr. Wang currently serves as the Chief Business Officer and Vice President for Program Management at Viva Biotech Ltd.

Chengbin Wu, PhD, VP, ChemPartner

Discussion Title: *Fully Integrated Biologics Platform to Support Therapeutic Antibody Development*

Dr. Chengbin Wu is VP Biologics at Shanghai ChemPartner. Previously he was the Volwiler Associate Fellow at Abbott, leading therapeutic antibody development programs from discovery through IND stage. He is the primary inventor of the DVD-Ig technology, a new generation platform for developing bi-specific antibodies. Since joining ChemPartner in 2010, Dr. Wu has established a world-class biologics platform that covers all major aspects of antibody preclinical research and development. His team has collaborated with a number of major pharmaceutical and biotech companies for therapeutic antibody development.

Charles (Yuanzan) Ye, CEO, Acesys Pharmatech

Discussion Title: *From China to USA Manufacturing*

Charles is CEO of Acesys Pharmatech since 2004. With more than 6 years of experience at Schering Plough Pharmaceutical Company as medicinal chemist and then financial analyst, Charles has extensive experience on drug discovery and financial management. He quit from Schering Plough and founded Acesys Pharmatech in Nanjing in 2004. Acesys Pharmatech is a Chemistry CRO company and moved to generic drug development and manufacturing three years ago. Through investment and acquisition, Acesys Pharmatech became the shareholder of a China based GMP manufacturing company and a USA based cGMP manufacturing company (API Inc). He designed and built Small Molecule Discovery Platform at China Medical City in 2009-2010.

Libing Yu, PhD, founder, CEO & Board Director, Alputon

Discussion Title: *Systematic Enhancement of CRO Productivity*

Dr. Libing Yu is founder, chief executive officer and board director of Alputon Inc., which provides CRO and CMO service to global pharmaceutical and biotech companies. Prior to Alputon, he was Director of Chemistry at ArQule Inc., leading internal and external research programs in lead discovery and optimization in drug discovery and managing development of chemical technologies including parallel

chemistry. Libing did his postdoctoral research focusing on new methodology development, green chemistry, carbohydrate chemistry and enzymatic synthesis at University of Miami, Florida. Libing received his Ph.D. in Organic Chemistry at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. He has co-authored over 40 publications and patents.

Xiang Yang Yu, PhD, Principal Investigator, Ironwood Pharmaceuticals

Discussion Title: *Global Outsourcing Strategies at Ironwood*

Dr. Yu is a principal investigator of medicinal chemistry at Ironwood Pharmaceuticals. She has been passionately involved in drug discovery programs in multiple therapeutical areas as well as efficiently and strategically managing external drug discovery collaborations in the US, Europe and Asia. Prior to joining Ironwood, Dr. Yu was Associate Director and then Director of Medicinal Chemistry at Epix Pharmaceuticals leading successful drug discovery programs. She was the project leader for S1P program licensed to Amgen for highly potent, selective and orally active agents for autoimmune diseases and a project leader for GSK collaborative discovery program which resulted in multiple milestone payments. She has led multiple anti-infectious programs at Activbiotics and Cubist Pharmaceuticals. She has extensive experience in advancing compounds from discovery screening to preclinical & clinical development. Dr. Yu obtained Ph.D. in Organic Chemistry from Florida State University and undergraduate degree from East China University of Science & Technology in Shanghai, China.



Jason Zhang, PhD, President, Acme Bioscience

Discussion Title: *Support Globalized Drug Discovery with a Reliable and Cost Effective Hybrid Model*

Dr. Jason Zhang is the Founder of Acme Bioscience, a chemistry based Contract Research Organization (CRO). He serves as President and Chief Executive Officer since its inception in 2001 in Palo Alto, California, and established its Shanghai research center in 2010. Prior to founding Acme Bioscience, he had been holding multiple research positions in medicinal chemistry at Microcide Pharmaceuticals and Essential Therapeutics from 1994 to 2002. Jason has over 20 years of drug discovery and development experience in a number of areas including antibacterial and antiviral research. Jason received his BS in Chemistry from Northwestern University, MS from Chinese Academy of Science, and his PhD and postdoctoral training in Organic Chemistry from Emory University.

John Mathias, PhD, Pfizer

Presentation Title: *Designing Oral & Inhaled p38a MAP Kinase Inhibitors to Treat Asthma & COPD*

John received his PhD with Prof Fraser Stoddart from Sheffield University in 1991 & Postdoctoral training with Prof George Whitesides at Harvard University from 1991-1993. He joined Pfizer in Sandwich in 1993 and has worked as a Medicinal Chemist in the areas of Anti-Virals, Sexual Health, Urology & Allergy & Respiratory leading compounds into the clinic versus an array of different molecular targets including PDE5 inhibitors, Alpha 1 Receptor Antagonists, PDE4 inhibitors & p38 inhibitors. In 2006 he became an Associate Research Fellow workng within the Lead Discovery Group in Sandwich. In Feb 2009 he became Global Head of the High Throughput Screening Centre of Emphasis, with responsibility for leading the HTS groups Hit Identification efforts for all of Pfizer's Research Units. In May 2011 he was appointed Head of Medicinal Chemistry for the Inflammation & Remodelling Group within the BioTherapeutics Chemistry Organisation.

Roger Tung, PhD, President &CEO, Concert Pharmaceuticals

Presentation Title: *Building a Biotech Company from the Ground Up*

Roger is the scientific founder, President, and Chief Executive Officer of Concert Pharmaceuticals, co-founded the company in April 2006. Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals; as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons. At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and has been granted 60 U.S. patents. He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich. Roger serves as a scientific advisor to public and private biotech companies and on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

CABA Leadership

President (2012-2013)

Philip Zhang, Ph.D., J.D.
Co-Managing Principal, Milstein Zhang & Wu LLC

President (2013-2014)

Xiang Yang Yu, Ph.D.
Principal Investigator, Ironwood Pharmaceuticals, Inc.

Vice Presidents

Zhiyong Yang, Ph.D.
Principal Scientist, Pfizer BioTherapeutics Research

Qinglin Che, Ph.D.
Research Scientist, Synta Pharmaceuticals

Sue Ma, M.D.
Scientist II, Novartis Institute of BioMedical Research

General Manager

Qingqing Cao, PhD
Senior Engineer, Becton Dickinson (BD)-Bioscience

CABA Legal Counsel

Fred Gilman, J.D.
Attorney, Lynch, DeSimone & Nylen, LLP

Board of Directors

Chaoyang Dai, Ph.D.;
CABA President (2010-2011)
VP of Operations, Acebright, Inc.

Jun Han, Ph.D.;
CABA Funding President
CEO, SOTA International LLC

Shiwen Lin, Ph.D.,
Chairman of the Board
Associate Director, Process & Analytical Technologies, Agenus, Inc.

Lixin Shen, Ph.D.
President and CEO, Wuxi Howfond Biopharma Co., Ltd. (China)

Zhao-Kui Wan, Ph.D.;
CABA President (2009-2010)
Sr. Principal Scientist, Pfizer Inc.

Yihan Wang, Ph.D.; Past Board Chair
Associate Director/Chemistry, ARIAD Pharmaceuticals, Inc.

Erxi Wu, Ph.D.
Assistant Prof., North Dakota State University

Junjun Wu, Ph.D.;
CABA President (2007-2009)
CEO，WuXi AllNature Biotech LLC (China)

Zhihong Chen, Ph.D.;
CABA President (2011-2012)
Principal Research Investigator, Eisai Research Institute

Executive Committee Members

Lan Cao, Ph.D.
Team Lead, Product Development, Organogenesis Inc.

Steven Du, MD, PhD, MBA
President & CEO, Long Pharmaceuticals

Ellen Fan
Sr. Scientist, Arsenal Medical

Kevin Fang, Ph. D.
Sr. Director of Medicinal Chemistry, Sunovion Pharmaceuticals

Henry Gu, J.D.
Counsel, WilmerHale

Fred Hu, Ph.D.
Executive Director, Discovery Chemistry Services, ChemPartner

Shengfang Jin, Ph.D.
Sr. Director/Biology, Agios Pharmaceuticals

Jinbo Lee, Ph.D.
President, Sage Partner International

Fushuang Liu
EVP, Wuxi Howfond Biopharma, Co. Ltd. (China)

Hao Li, Ph.D.
Associate Director, Novartis

Susan Qu, Ph.D. MBA
Principal Project Manager, Genzyme Corporation, a division of Sanofi

Ji Shi
Consultant, , Simon-Kucher & Partners

Wendy Wang, MBA
Sr. Project Manager, *Genzyme Corporation, a division of Sanofi*

Yikai Wang, Ph.D.
The Broad Institute

Yongzhong Wang, Ph. D.
Deputy General Manager, Kanghong Biotechnology Co. Ltd.,(China)

Yueming Wang, MBA
Deputy General Manager, Tide Pharmaceutical Co. Ltd. (China)

Zhigang Wang, Ph. D.
Sr. Principal Scientist, Avila Therapeutics

Shallwei Sun
General Manager, Callisyn Biomedical

Ze Tian, Ph.D.
Instructor, Dana Farber Cancer Institute/Harvard Medical School

Li Xing, Ph.D.
Senior principal scientist Pfizer

Wei Zhang, Ph.D.
Staff Scientist, Siemens Healthcare Diagnostics

Weiyi (Wendy) Zhang, Ph.D.
President, Boston Lincoln International

Youxin Zhang, Ph.D.
Senior Consultant, Navigant Consulting

Liping Zhou, Ph.D.
principal scientist, Novartis Pharmaceutical Company

Zhendong Zhu, Ph.D.
Sr. Principal Scientist, Avila Therapeutics

CABA Advisors

Youssef Bennani, Ph. D.
Vice President/Discovery Chemistry, Vertex Pharmaceuticals Inc.

Tim Clackson, Ph. D.
President of Research and Development and Chief Scientific Officer, Ariad Pharmaceuticals Inc.

Yuan-Hua Ding, Ph.D.
Senior Director & Head of External R&D Innovation - Asia, Pfizer

Pierre Dodion, M. D., MBA
Sr. VP, Corporate Development, Ariad Pharmaceuticals Inc.

Chen Li, Ph. D.
CEO, Hua Medicine (China)

Luck Li, Ph.D.
Exec Director, Head of Global Biotherapeutic Technologies, Bio-Innovation, Pfizer

Yuanli Liu, Ph. D.
Director of China Initiative, Harvard School of Public Health

Dawei Ma , Ph. D.
Professor, Shanghai Institute of Organic Chemistry (China)

Tarek Mansour, Ph. D.
EVP of Research & Development, Xenon Pharmaceuticals (Canada)

Shi Li, Ph. D.
CEO, Zerun Biotechnology (China)

Tse Ping
Chairman, Sino Biopharmaceutical Ltd. (China)

John Piwinski, Ph. D.
Principal, JJPiwinski Pharma Consulting LLC

Steve Projan, Ph. D.
Sr. V.P. R&D, Innovative Medicines Head of Infectious Diseases & Vaccines, MedImmune

Tomi Sawyer, Ph. D.
Chief Scientific Officer and Senior Vice-President, Aileron Therapeutics

Liming Shao, Ph. D.
Professor, Fudan University (China)

Suvit Thaisrivongs, Ph. D.
Vice President, Pfizer, Inc.

Roger Tung, Ph. D.
CEO, Concert Pharmaceuticals

Yibin Xiang, Ph. D.
Sr. Director, Medicinal Chemistry, Genzyme

Gangfeng Xu, Ph. D.
Divisional Vice President, Corporate Licensing & Acquisitions at Abbott Laboratories

Steve Yang, Ph. D.
Head of R&D, Asia & Emerging Markets, AstraZeneca

Howard Yuwen, Ph. D.
Executive Director, Regulatory North America, Alexicon Pharmaceuticals

东莞松山湖高新技术产业开发区

东莞松山湖高新技术产业开发区 2001 年 11 月经广东省人民政府批准设立，2010 年 9 月经国务院批准为国家高新技术产业开发区。松山湖坐落于“广深港”黄金走廊腹地，地处东莞几何中心，南临香港、深圳，北靠广州，地理位置十分优越。园区规划控制面积 72 平方公里，坐拥 8 平方公里的淡水湖和 14 平方公里的生态绿地，是一个在国内具有示范意义、人与自然和谐共存的科技新城。

松山湖是东莞“科学发展示范区、转型升级引领区”，力争打造珠三角乃至全国产业转型的科技中心，为广东探索科学发展新模式提供示范。园区先后被授予“中国最具发展潜力的高新技术产业开发区”、“跨国公司最佳投资开发区”、“信息产业国家高技术产业基地”、“国家火炬创新创业园”、“省部共建中国东莞留学人员创业园”、“粤港澳文化创意产业实验园区”等荣誉称号，其中松山湖台湾高科技园还与深圳前海、广州南沙和珠海横琴等被共同列为广东省重大合作平台，成为广东省探索重大平台建设新模式的重要基地。

松山湖把招商重点放在“三大产业”上，即发展壮大高端电子信息产业，主要招引新一代通讯电子、关键电子元器件、高端电子装备、新型通信材料等电子领域项目；全力打造生物医药产业，加快建设东莞两岸生物技术产业合作基地，争取成为国家级生物技术产业基地；积极推进现代服务业，主要包括现代金融服务业和文化创意产业。

松山湖坚持“融山、水、园为一体”、“科技共山水一色”等彰显生态特色的规划理念，努力优化城市生态环境，实现人与自然的和谐共处，经济社会与资源环境的协调发展，将成为一个具有高科技含量和高生态含量，宜居宜商的国际化创新城市。

松山湖区位交通

莞台生物技术合作育成中心

东莞两岸生物技术产业合作基地

东莞两岸生物技术产业合作基地是东莞市积极把握产业发展机遇，打造产业转型升级的重要基地，是广东省促进生物技术产业发展的重要平台。基地得到了省、市的大力支持，广东省成立了以省委常委、常务副省长任组长的基地建设支持小组，东莞市成立了由市长任组长的基地建设领导小组，全力支持基地开发建设。基地核心区位于松山湖高新技术产业开发区，由东莞市投入 95 亿人民币用于开发建设，是东莞“三重”项目的重中之重。基地以生物医药为主体，重点发展新药及生物仿制药、先进医疗器械与设备、基因产业、中药研发、健康产业及生物服务业等。基地将通过莞台合作的优势，争取国家政策，创建绿色通道，努力成为一个适合生物技术企业创业的沃土和实现生物技术企业梦想的美好家园。

东莞市生物技术产业发展有限公司

东莞市生物技术产业发展有限公司是一家国有独资的生物技术管理和服务公司，成立于 2012 年 12 月 20 日，注册资本 2 亿人民币，是东莞两岸生物技术产业合作基地的开发主体。公司组建了专业、精简、高效的管理团队，负责两岸基地的运营管理。

公司负责两岸基地的土地开发和基础设施建设、提供生物技术产业项目的投融资服务、在新药开发、技术转让、技术咨询等方面提供完善的服务体系。

东莞市生物技术产业发展有限公司将借鉴国内相关国资公司的优秀经验，建立起优质的运营和管理体系，推进两岸基地的招商和载体建设等各项工作，努力将基地建成海峡两岸重大战略合作项目，推动基地成为国家级生物技术产业基地，为东莞的产业转型升级做出更大的贡献。



松山湖功能分区

松山湖管委会办公区

Golden Sponsor

Pfizer

药明康德 WuXi AppTec

Anichem

SSL 松山湖 SONG SHAN LAKE

Sundia

Silver Sponsor

ARIAD

Ironwood

SANOFI

Acme Bio

ACESYS

Alputon Inc.

Akesobio 中山康方生物医药有限公司

BOL Boston Open Labs

PHARMA TECH

EMERALD BIO

H3 BIOMEDICINE

Milstein Zhang & Wu LLC

Piramal | Healthcare knowledge action care

IVA

Conference Sponsor

CHEM PARTNER SHANGHAI CHEMPARTNER

A Chemtek

PTM Biolabs, Inc.

BIODURO

GENEWIZ Solid science. Superior service.

Luknova

spectrum chemicals & laboratory products

REGIS TECHNOLOGIES, INC.

Wyzen WB Biosciences

abcam discover more

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials.

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.

CABA Mission

• To promote science, technology, and business collaboration in biotech/pharmaceutical industry;

• To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;

• To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;

• To embrace advancement of science and commercialization of innovation that will benefit human health;

• To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at cabaconnect@gmail.com. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org
Email: cabaconnect@gmail.com
Address: P. O. Box 600241, Newtonville, MA 02460